Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Abdul Latif Bikak

Advanced Heart Failure and Transplant Cardiology Marietta, GA Medical Doctor

NPI 1578827234 CMS profile 1386096

175 White St Nw Ste 100, Marietta, GA 30060

Open in the dashboard

General payments

$213,678

479 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$60,561 paid to institutions, not to them · program years 2024–2025

Through program year 2025, Abdul Latif Bikak of Marietta, GA is reported in the CMS Open Payments database as having received $213,678 across 479 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $60,561 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Advanced Heart Failure and Transplant Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $129,774 145
2024 General $64,178 115
2023 General $8,865 58
2022 General $8,228 55
2021 General $964 55
2020 General $405 19
2019 General $1,264 32

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Abdul Latif Bikak
  • Advanced Heart Failure and Transplant Cardiology median
  • Middle half of Advanced Heart Failure and Transplant Cardiology
  • National median

In program year 2025, general payments to Abdul Latif Bikak were reported at $129,774. Among 967 Advanced Heart Failure and Transplant Cardiology profiles paid that year, the median was $1,024 and the middle half received between $289 and $6,890.

Show as a table
Year Abdul Latif Bikak Advanced Heart Failure and Transplant Cardiology median Middle half National median
2019 $1,264 $863 $224–$4,562 $163
2020 $405 $452 $122–$3,992 $114
2021 $964 $550 $159–$3,571 $132
2022 $8,228 $729 $221–$4,357 $149
2023 $8,865 $1,002 $309–$5,827 $160
2024 $64,178 $931 $273–$5,204 $164
2025 $129,774 $1,024 $289–$6,890 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alnylam Pharmaceuticals Inc. $164,986 151 payments
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $16,990 47 payments
  3. Lilly USA, LLC $12,116 15 payments
  4. Pfizer Inc. $7,069 28 payments
  5. AstraZeneca Pharmaceuticals LP $4,386 19 payments
  6. Abbott Laboratories $3,020 46 payments
  7. Abiomed $715 5 payments
  8. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $611 44 payments
  9. CVRx, Inc. $544 8 payments
  10. Actelion Pharmaceuticals US, Inc. $543 13 payments
  11. Other $2,697 103 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $176,610 57 payments
  2. Travel and Lodging $22,176 68 payments
  3. Food and Beverage $12,326 352 payments
  4. Consulting Fee $2,558 1 payment
  5. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. AMVUTTRA Genetic Disease $153,305 129 payments
  2. JARDIANCE Diabetes $8,643 14 payments
  3. JARDIANCE Diabetes $8,346 33 payments
  4. VYNDAQEL $7,036 26 payments
  5. JARDIANCE Diabetes $6,836 9 payments
  6. AMVUTTRA Not Applicable $6,700 10 payments
  7. LOKELMA $4,198 9 payments
  8. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $1,576 10 payments
  9. Impella $715 5 payments
  10. LifeVest $611 44 payments
  11. Other $6,500 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

1,595

Median for Advanced Heart Failure and Transplant Cardiology: 1,489

Drug cost

$3,174,855

Median for Advanced Heart Failure and Transplant Cardiology: $885,869

Branded share of claims

39.2%

Median for Advanced Heart Failure and Transplant Cardiology: 32.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vyndamax Tafamidis Brand 71 $1,980,348
Vyndaqel Tafamidis Meglumine Brand 19 $420,134
Entresto Sacubitril/Valsartan Brand 224 $283,729
Jardiance Empagliflozin Brand 167 $193,516
Camzyos Mavacamten Brand 23 $171,369
Eliquis Apixaban Brand 45 $44,823
Ozempic Semaglutide Brand 36 $43,363
Farxiga Dapagliflozin Propanediol Brand 27 $23,455
Torsemide Generic 69 $1,762
Metoprolol Succinate Generic 143 $1,710

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 800 Part D prescribers listed as Advanced Heart Failure and Transplant Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 26 billing codes

Paid by Medicare

$29,911

Medicare's payments for the services billed

Medicare patients

164

Average age 72

Services billed

504

74 women, 90 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Atrial fibrillation 64%
Chronic kidney disease 57%
Arthritis 53%
Diabetes 52%
Depression 32%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
AMVUTTRA
  • Alnylam Pharmaceuticals Inc. $49,239
$49,239 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $8,598
  • Lilly USA, LLC $4,295
$12,893 167 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $183
$183 224 —
ONPATTRO
  • Alnylam Pharmaceuticals Inc. $125
$125 — —
WINREVAIR
  • Merck Sharp & Dohme Corporation $106
$106 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

479 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Advanced Heart Failure and Transplant Cardiology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record